Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial


Novavax Inc’s COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval.

There were no cases of severe illness or deaths among those who got the vaccine.

The vaccine was also about 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the UK. It was about 90% effective overall, combining data from people infected with both versions of the coronavirus.

In a smaller trial conducted in South Africa – where volunteers were primarily exposed to another newer, more contagious variant widely circulating there and spreading around the world – the Novavax vaccine was only around 55% effective but still fully prevented severe illness and death.

Results from the final analysis of the UK trial were largely in line with interim data released in January.